eRapport

Ultrasound-directed diagnosis and targeted treatment of Crohn’s disease using smartbubbles

Prosjekt
Prosjektnummer
911865
Ansvarlig person
Kim Nylund
Institusjon
Helse Bergen HF
Prosjektkategori
Postdoktorstipend
Helsekategori
Oral and Gastrointestinal
Forskningsaktivitet
4. Detection and Diagnosis, 6. Treatment Evaluation
Rapporter
2022 - sluttrapport
There were 3 workpackages (WP) included in the project application. In WP-1 part 1 we did not succeed in constructing a new microbubble for perfusion measurement or test our perfusion model in rats. We wanted to use Sonazoid instead, but this bubble could not be used in animal studies using our perfusion method as the microbubbles were too solid burst using the animal ultrasound scanner. We did however test our perfusion model and compared it with MRI together with our Czech collaborators and the data was published in 2014 by Jirik et. al. This was a goal of in WP-1, part 2 although we use a different reference standard. We also tested the intra- and interrater variability and variability between ultrasound scanners of the perfusion model in a clinical setting (Stangeland, 2017 and Engjom, 2018) In WP-2 there were two clinical studies. A cross sectional study (CS-1) and longitudinal study (CS-2). In the first attempt at CS-1 that data could not be published unfortunately due to changes in the sofware and hardware of our ultrasound scanner making the data impossible to compare with histology. We chose to change or reference standard to the validated endoscopy score Simple endoscopic score of Crohn's disease since there were no validated histological scores and started a new study. This was designed both to look at cross sectional data and longitudinal data. The cross sectional data have now been analysed and while both bowel wall thickness and the thickness of individual bowel wall layers clearly predict endoscopic activity only some parameters of contrast-enhancement correlate with endoscopic disease activity. The analysis of contrast enhancement also requires a multi step approach and long post-processing which renders it very impractical in a clinical setting. The first attempt at CS-2 was performed in Norway, but inclusion was stopped due to lack of progress. The main outcome of remission could not be examined as there were too few patients in activity group at the endpoint, but nevertheless as we found that a secondary outcome (treatment failure) could be analysed and that patients with treatment effect . The second attempt was performed as a part of a research stay at Academisch Medish Centrum in Amsterdam, the Netherlands. This study was finalised an published in 2022 and the results indicate that gastroinestinal ultrasound is well suited for predicting both treatment respons and remission. However, this can simply be done by measuring bowel wall thickness and use of contrast and perfusion measurements does not seem to improve results. Finally, we did we did not succeed in fulfilling the goals in WP -3. The drug we intended to use for the study went out of production and could not longer be aquired. There were no other candidate drugs that could fit with the intended delivery mechanism. We have with our project shown that diagnostic ultrasound is well suited for detecting disease activity in comparison with endoscopy. A score based on bowel wall thickness and colour Doppler is also directly related to the degree of activity on endoscopy . Gastrointestinal ultrasound can also be used for predicting both treatment response and remission. Although the use of contrast ultrasound for measuring perfusion is reproducible and does reveal differences related to treatment response, it does not seem to improve diagnostics to a degree that justifies using it in the follow up of patients.
2021
The project is almost finished, but still some minor work remains on data-analysis and publication of results.The data-analysis on the cohort in Amsterdam has been finished and the paper was recently submitted to Journal of Crohns and Colitis. The data analysis from the cohort in Bergen is almost finished. An abstract on parts of the remaining longitudinal data from the Norwegian cohort has been accepted for presentation at the yearly meeting of Norsk Gastroenterologisk Forening and European Crohns and Colitis Organisation. The data from the Dutch cohort are also presented at ECCO 2022. Both conferences are held in February 2022. Finally, data from the Dutch cohort have also been submitted to Digestive Disease Week 2022. In 2021 I was also co-author on a systematic review and expert consensus paper on defining ultrasound response and remission in IBD.
2020
Still work remains on data-analysis and publication on some remaining results, particularly data on contrast-enhanced ultrasound.Due to conflicting tasks with other projects, the data-analysis both on the cohort in Amsterdam and on the data from the cohort in Bergen has not been finished. Particularly the contrast data requires a lot of post-processing that is time-consuming. The work is still ongoing, however, and will continue through 2021. At the 15th Ecco meeting in Vienna, Austria in February 2020. The posters “Expert consensus on acquisition and reporting of intestinal ultrasonography activity in Crohn’s disease. A prospective inter-rater agreement study (P-176)» and “Gastrointestinal ultrasound is an accurate marker for endoscopic activity in Crohn's disease (P143)» were presented. Fredrik Bjorvatn Sævik defended his thesis :"Ultrasonographic evaluation of disease activity in Crohn’s Disease" on the September 21st 2020. Three project related papers have been published in 2020 of which all were original papers. I was also co-author on a position paper EFSUMB on gastrointestinal ultrasound in intestinal emergencies.
2019
Inclusion in the clinical studies is over, but still some follow up examinations remain. Work on analysis and writing on manuscripts is estimated to finish spring 2020.In Amsterdam 40 patients have been included in the longitudinal study while in Bergen 64 patients have been included. Inclusions in both studies have stopped and only follow-up examinations remain. The data-analysis is ongoing in both studies and in January 2020 a collaborator in Amsterdam visited Bergen to go through the analysis of contrast-enhanced ultrasound recordings using Vuebox. The plan is to continue the data-analysis in these studies and start on manuscripts during the spring 2020. Since there are remaining funds in the project, I have applied for an extension of the project period to 31. May 2020. In Trondheim at the annual meeting in the Norwegian ultrasound association (NFUD) from 3.-5. April two abstracts related to the project was presented: “Ultralyd tarm kan brukes til å skille mellom remisjon og aktiv sykdom ved Crohns sykdom” and “Kvantifisering av kontrastforsterket ultralyd ved Crohn sykdom – sammenligning av ulike metoder». Corresponding abstracts were also presented at the annual European Ultrasound meeting, Euroson, in Madrid 30. May-1. June; “Gastrointestinal ultrasound to separate remission from active Crohn’s disease” and “Quantification of contrast-enhanced ultrasound in Crohn’s disease – a comparison of different approaches.” In this final abstract several different ways of analysing contrast-enhanced ultrasound data were compared and interestingly simple, relative methods revealed similar results to more advanced perfusion methods when compared to endoscopy. This is an argument for using these simple methods in a clinical setting. Finally, a popular science paper called: “Nye retningslinjer for kontrastforsterket ultralyd,” was published in Best Practice 29. May. Two project related papers are currently in the pipeline. The first paper “Gastrointestinal ultrasound can predict endoscopic activity in Crohn’s disease,” have been submitted to Ultraschall in der Medizin and was accepted with minor revision. A revised manuscript has been submitted and we are currently awaiting the peer-review. The second paper: “Development and Validation of a Simple Ultrasonographic Activity Score for Crohn’s disease,” is currently in manuscript form, but will submitted within a couple of weeks to Journal of Crohns and Colitis. In the same period I was an invited speaker at an EFSUMB webinar “Elastography for small parts” on the 25. April with the lecture “Elastography of the GI tract,” and at UEGW 19.-23. October with the lecture “Ultrasound elastography in IBD.” I was also a co-author on two position papers on gastrointestinal ultrasound from EFSUMB: “EFSUMB Gastrointestinal Ultrasound (GIUS) Task Force Group: Celiac sprue and other rare gastrointestinal diseases ultrasound features.” and “EFSUMB Position Paper: Recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis.” Finally, I was co author on a paper studying the use of endorectal ultrasound for tumor staging: “Endorectal ultrasound and magnetic resonance imaging for staging of early rectal cancers: how well does it work in practice?”
2018
Inclusions are still ongoing in the clinical studies and will continue through the spring of 2019. Two papers investigating the reproducbility of the perfusion measurements in patients were published this year.In Amsterdam 30 patients have been included in the longitudinal study while in Bergen 55 patients have been included in CS-2. Inclusions are continuing in both studies. We estimate that inclusions will stop during spring 2019. The paper "Interobserver Analysis of CEUS-Derived Perfusion in Fibrotic and Inflammatory Crohn’s Disease" was accepted and e-published in Ultraschall in der medizin this year. In this paper we could show that there was a low interobserver variability for several of the perfusion parameters derived from a commercially available software for perfusion analysis by scaling the data. We also found that there was a difference in perfusion between patients with fibrotic and inflammatory Crohn's disease. The paper "Contrast-enhanced ultrasonography of the pancreas shows impaired perfusion in pancreas insufficient cystic fibrosis patients" was also published in Biomed Central Imaging. In this study we used the "bolus-and-burst" algorithm where absolute perfusion parameters are calculated in the pancreas and found there was substantial interobserver agreement for the mean transit time. This is quite interesting since the variability between observers when analyzing the mean transit time using the commercial method was very high. In the same period I was invited speaker at EUROSON in Poznan, Poland, with the lecture “How to scan the GI tract using ultrasound,” and at the UEGW in Vienna, Austria, with the lectures: “First look at stomach and bowel – typical positions," "Basic methodology: How to scan?" and "CEUS in IBD patients-any value?" Guidelines and recommendations for gastrointestinal ultrasound in inflammatory bowel disease on which I was second author was published this year by EFSUMB in Ultraschall in der medizin. I was also co-author on an EFSUMB Position Paper: Recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis which was published january 2019. A systematic review on which I was second author "Ultrasound for assessing disease activity in IBD patients: a systematic review of activity scores" was also published in journal of Crohns and Colitis.
2017
The research stay at Academisch Medish Centrum in Amsterdam, Holland, was continued and finalized. Inclusion continued in clinical studies and the study period was extended to include a sufficient number of patients.During the 2 months continuation of my research collaboration with the group of GRAM D’Haens patients were included in the longitudinal study. Also, in the same period I commuted back to Bergen and Haukeland University Hospital and included patients in the corresponding clinical study in CS-2. In the clinical follow up study currently 42 patients have been included. This is not sufficient and we have asked the regional ethics committee for an extension of the inclusion period. We have had some challenges with the software used for analyzing the bolus and burst perfusion, but are currently working on solving this problem. One technical paper on the bolus and burst perfusion method with contrast-enhanced ultrasound on which I was first author was published in Ultrasound international open. The paper investigating inter-observer variability for the analysis of perfusion using the bolus and burst method is still under review. The paper investigating inter-observer variability for the analysis of perfusion using contrast-enhanced ultrasound in Crohn’s patients with commercially available software was accepted for publication in Eur J Ultrasound (Ultraschall in der Medizin) and is currently in press. In the same period I was invited speaker at EUROSON in Ljublana, Slovenia, with the lecture “The value of applying CEUS and elastography in Crohns disease,” and at the UEGW in Barcelona, Spain, with the lecture: “Any added value of CEUS and elastography in Crohn’s disease.” Guidelines and recommendations for gastrointestinal ultrasound in inflammatory bowel disease on which I was second author was submitted by EFSUMB to Ultraschall in der Medizin and accepted for publication, and Hilde von Volkmann published a second paper as a part of her PhD examining motility on a genetic diarrheal disorder where I am last author and co-supervisor.

As most of this project consists of early testing of the potential of a diagnostic ultrasound to predict treatment outcomes we did not include user participation. If some of the diagnostic methods we investigate show promise the next step would be to implement them in larger clinical trials and include user participants in the planning of these studies.

2016
A 6 months research stay was performed at Academisch Medish Centrum in Amsterdam, Holland in collaboration with Professor GRAM D’Haens. Patients were included in a clinical follow up study (CS-2) both in Amsterdam and in Bergen.During the 6 months research stay research collaboration with the group of GRAM D’Haens was initiated. A protocol for a longitudinal ultrasound study of Crohn’s patients was accepted by the local ethics committee at the AMC and the study inclusion initiated in April. In the same period I commuted back to Bergen and Haukeland University Hospital and could include patients in the corresponding clinical study in CS-2. An elongation of my stay in Amsterdam was planned for the period 1st March 2017 to 30th April 2017 to continue inclusion and data analysis. Two technical papers on the bolus-and-burst perfusion method with contrast-enhanced ultrasound was submitted for publication investigating inter-observer variability for the analysis, inter-observer variability for repeated examinations on the same scanner and for repeated measurements on different ultrasound scanners. These are all important features of a perfusion method for it to be repeatable and applicable by different investigators. Currently, there are no ultrasound perfusion methods that can be compared between different ultrasound scanners severely limiting the clinical usefulness. We found that using the bolus-and-burst method perfusions measurements can be compared between different scanners. The first paper was rejected and will be resubmitted to another journal early in 2017. The second paper has been accepted with minor revision. A third paper was also submitted investigating the inter-observer variability for analysis using commercially available perfusion analysis software for contrast-enhanced ultrasound. This paper has been resubmitted after revision and we are awaiting the decision. In the same period recommendations and guidelines for gastrointestinal ultrasound was published by the EFSUMB on which I was the first author, and Hilde von Volkmann published an ultrasound study on a genetic diarrheal disorder as a part of her PhD where I am co-supervisor and 2nd author.
2015
Two basic studies on ultrasound perfusion were published and inclusion for a clinical trial on Crohn's disease using Sonazoid and Sonovue to asess perfusion, was startedA three week research stay in Bologna was performed, but the clinical study is planned at the Academish Medish Centrum (AMC) in Amsterdam, Holland, in collaboration with Professor GRAM D’Haens. The AMC and GRAM D’Haens have considerable experience and expertise in performing clinical studies on patients with inflammatory bowel disease. This research stay is scheduled from March 1st to August 31st 2016. The modified protocol of clinical study 2 was submitted to the regional ethics comittee at Haukeland University Hospital and inclusion started in May. In part of the protocol Sonazoid is used as the contrast agent. Ethical approval for interobserver analysis have been obtained and the performance of Sonovue and Sonazoid will be compared to see which performs better. A similar protocol was submitted to the AMC enabling a multi-senter trial. Data from CS-1 was analyzed. There was however issues with the quality of the contrast recordings in this study since extensive software changes had been made on the clinical scanner during the trial making comparison problematic. The publication of these data are currently on hold and we are considering writing a paper on the remaining ultrasound data without the contrast data. A phantom study of was published with our international collaborator Radovan Jirik testing different approaches for calculating the arterial input function with contrast-enhanced ultrasound perfusion. This is directly related to laboratory study 2 in WP-1 where we are working on validation 2 D CEUS “Bolus and burst” perfusion model. Also a preliminary study comparing CEUS perfusion in mice tumors with MRI perfusion was published in 2015.
2014
Inclusion in clinical studies have stopped and the results of one of these studies was published. The main finding in this paper was that Crohn patients with effective treatment had reduced blood flow already one month into the treatment which indicates that we can use these measurements to predict treatment effect.During the first 6 months of the postdoc period I have ended inclusion in CS-1 and CS-2. The inclusion in CS-2 was stopped due to lack of progress. Data of CS-1 and CS-2 was analysed and and a paper was drafted from the data in CS-2 and published. Due to the low number of included patients we could not examine remission as an endpoint. Several patients had treatment failure during the observation period however and for this end point we found very interesting results. Our findings indicate that patients with effective treatment has lower perfusion in the affected gastrointestinal already one month into the treatment. This has implications since we usually evaluate treatment effect after three months. If predictions can be made earlier this may both make the treatment better for the patients but also reduce cost. Data analysis of CS-1 has not been finished and will continue in spring 2015. A modified protocol of CS-2 has been drafted for the Research stay in Bologna in the spring. The hospital in Bologna is serving a large cohort of Crohn's patients and is ideal for making longitudinal studies. More patients included will enable us to examine end points such as clinical and endoscopic remission. In 2014 Sonazoid has been registered in Norway for clinical use. This could be better for studying perfusion than Sonovue as it has a more uniform size distribution. Since it already as been approved for use in humans it has the great advantage that it can be implemented quickly in clinical work if it performs well. Instead of trying to design a new microbubble, we intend to use this in WP-1 for testing of reproducibility of the bolus and burst method and for validation. Two other papers related to perfusion analysis of contrast enhanced ultrasound based on previous work was published in 2014.
Vitenskapelige artikler
de Voogd F, Bots S, Gecse K, Gilja OH, D'Haens G, Nylund K

Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn's Disease.

J Crohns Colitis 2022 Nov 01;16(10):1598.

PMID: 35639823

Ilvemark JFKF, Hansen T, Goodsall TM, Seidelin JB, Al-Farhan H, Allocca M, Begun J, Bryant RV, Carter D, Christensen B, Dubinsky MC, Gecse KB, Kucharzik T, Lu C, Maaser C, Maconi G, Nylund K, Palmela C, Wilson SR, Novak K, Wilkens R

Defining transabdominal Intestinal Ultrasound treatment response and remission in Inflammatory Bowel Disease: Systematic review and expert consensus statement.

J Crohns Colitis 2021 Oct 06. Epub 2021 okt 6

PMID: 34614172

Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, Allocca M, Maconi G, de Voogd F, Christensen B, Vaughan R, Palmela C, Carter D, Wilkens R

Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease.

J Crohns Colitis 2021 Apr 06;15(4):609-616.

PMID: 33098642

Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K

Development and Validation of a Simple Ultrasound Activity Score for Crohn's Disease.

J Crohns Colitis 2021 Jan 13;15(1):115-124.

PMID: 32504533

Sævik F, Gilja OH, Nylund K

Gastrointestinal Ultrasound Can Predict Endoscopic Activity in Crohn's Disease.

Ultraschall Med 2022 Feb;43(1):82. Epub 2020 apr 24

PMID: 32330994

Hollerweger A, Maconi G, Ripolles T, Nylund K, Higginson A, Serra C, Dietrich CF, Dirks K, Gilja OH

Gastrointestinal Ultrasound (GIUS) in Intestinal Emergencies - An EFSUMB Position Paper.

Ultraschall Med 2020 Dec;41(6):646-657. Epub 2020 apr 20

PMID: 32311749

Dietrich CF, Hollerweger A, Dirks K, Higginson A, Serra C, Calabrese E, Dong Y, Hausken T, Maconi G, Mihmanli I, Nürnberg D, Nylund K, Pallotta N, Ripollés T, Romanini L, Saftoiu A, Sporea I, Wüstner M, Maaser C, Gilja OH

EFSUMB Gastrointestinal Ultrasound (GIUS) Task Force Group: Celiac sprue and other rare gastrointestinal diseases ultrasound features.

Med Ultrason 2019 Aug 31;21(3):299-315.

PMID: 31476211

Oien K, Forsmo HM, Rösler C, Nylund K, Waage JE, Pfeffer F

Endorectal ultrasound and magnetic resonance imaging for staging of early rectal cancers: how well does it work in practice?

Acta Oncol 2019;58(sup1):S49-S54. Epub 2019 feb 8

PMID: 30736712

Dirks K, Calabrese E, Dietrich CF, Gilja OH, Hausken T, Higginson A, Hollerweger A, Maconi G, Maaser C, Nuernberg D, Nylund K, Pallotta N, Ripolles T, Romanini L, Saftoiu A, Serra C, Wüstner M, Sporea I

EFSUMB Position Paper: Recommendations for Gastrointestinal Ultrasound (GIUS) in Acute Appendicitis and Diverticulitis.

Ultraschall Med 2019 Apr;40(2):163-175. Epub 2019 jan 7

PMID: 30616263

Engjom T, Nylund K, Erchinger F, Stangeland M, Lærum BN, Mézl M, Jirík R, Gilja OH, Dimcevski G

Contrast-enhanced ultrasonography of the pancreas shows impaired perfusion in pancreas insufficient cystic fibrosis patients.

BMC Med Imaging 2018 05 15;18(1):14. Epub 2018 mai 15

PMID: 29764411

Bots S, Nylund K, Löwenberg M, Gecse K, Gilja OH, D'Haens G

Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores.

J Crohns Colitis 2018 Jul 30;12(8):920-929.

PMID: 29684200

Maconi G, Nylund K, Ripolles T, Calabrese E, Dirks K, Dietrich CF, Hollerweger A, Sporea I, Saftoiu A, Maaser C, Hausken T, Higginson AP, Nürnberg D, Pallotta N, Romanini L, Serra C, Gilja OH

EFSUMB Recommendations and Clinical Guidelines for Intestinal Ultrasound (GIUS) in Inflammatory Bowel Diseases.

Ultraschall Med 2018 Jun;39(3):304-317. Epub 2018 mar 22

PMID: 29566419

Nylund K, Sævik F, Leh S, Pfeffer F, Hausken T, Gilja OH

Interobserver Analysis of CEUS-Derived Perfusion in Fibrotic and Inflammatory Crohn's Disease.

Ultraschall Med 2019 Feb;40(1):76-84. Epub 2018 mar 14

PMID: 29539644

von Volkmann HL, Brønstad I, Gilja OH, R Tronstad R, Sangnes DA, Nortvedt R, Hausken T, Dimcevski G, Fiskerstrand T, Nylund K

Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation.

PLoS One 2017;12(9):e0185496. Epub 2017 sep 28

PMID: 28957388

Stangeland M, Engjom T, Mezl M, Jirik R, Gilja OH, Dimcevski G, Nylund K

Interobserver Variation of the Bolus-and-Burst Method for Pancreatic Perfusion with Dynamic - Contrast-Enhanced Ultrasound.

Ultrasound Int Open 2017 Jun;3(3):E99-E106. Epub 2017 sep 12

PMID: 28932826

von Volkmann HL, Nylund K, Tronstad RR, Hovdenak N, Hausken T, Fiskerstrand T, Gilja OH

An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.

Scand J Gastroenterol 2016 Nov;51(11):1308-15. Epub 2016 jun 24

PMID: 27338166

Nylund K, Maconi G, Hollerweger A, Ripolles T, Pallotta N, Higginson A, Serra C, Dietrich CF, Sporea I, Saftoiu A, Dirks K, Hausken T, Calabrese E, Romanini L, Maaser C, Nuernberg D, Gilja OH

EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound.

Ultraschall Med 2017 Jun;38(3):273-284. Epub 2016 sep 7

PMID: 27604051

Nylund K, Maconi G, Hollerweger A, Ripolles T, Pallotta N, Higginson A, Serra C, Dietrich CF, Sporea I, Saftoiu A, Dirks K, Hausken T, Calabrese E, Romanini L, Maaser C, Nuernberg D, Gilja OH

EFSUMB Recommendations and Guidelines for Gastrointestinal Ultrasound.

Ultraschall Med 2017 Jun;38(3):e1-e15. Epub 2016 sep 7

PMID: 27604052

Mezl M, Jirik R, Harabis V, Kolar R, Standara M, Nylund K, Gilja OH, Taxt T

Absolute ultrasound perfusion parameter quantification of a tissue-mimicking phantom using bolus tracking [Correspondence].

IEEE Trans Ultrason Ferroelectr Freq Control 2015 May;62(5):983-7.

PMID: 25965688

Arteaga-Marrero N, Rygh CB, Mainou-Gomez JF, Nylund K, Roehrich D, Heggdal J, Matulaniec P, Gilja OH, Reed RK, Svensson L, Lutay N, Olsen DR

Multimodal approach to assess tumour vasculature and potential treatment effect with DCE-US and DCE-MRI quantification in CWR22 prostate tumour xenografts.

Contrast Media Mol Imaging 2015 Nov;10(6):428-37. Epub 2015 mai 26

PMID: 26010530

Saevik Fredrik, Nylund Kim, Hausken Trygve, Ødegaard Svein, Gilja Odd H

Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn's disease.

Inflamm Bowel Dis 2014 Nov;20(11):2029-37.

PMID: 25185684

Schäfer S, Nylund K, Sævik F, Engjom T, Mézl M, Jirík R, Dimcevski G, Gilja OH, Tönnies K

Semi-automatic motion compensation of contrast-enhanced ultrasound images from abdominal organs for perfusion analysis.

Comput Biol Med 2015 Aug;63():229-37. Epub 2014 okt 17

PMID: 25453358

Jirik Radovan, Soucek Karel, Mezl Martin, Bartos Michal, Drazanova Eva, Drafi Frantisek, Grossova Lucie, Kratochvila Jiei, Macic?ek Ondr?ej, Nylund Kim, Hampl Ales, Gilja Odd Helge, Taxt Torfinn, Starcuk Zenon

Blind deconvolution in dynamic contrast-enhanced MRI and ultrasound.

Conf Proc IEEE Eng Med Biol Soc 2014 Aug;2014():4276-4279.

PMID: 25570937

Doktorgrader
Fredrik Bjorvatn Sævik

Ultrasonographic evaluation of disease activity in Crohn’s Disease

Disputert:
september 2020
Hovedveileder:
Kim Nylund
Deltagere
  • Torfinn Taxt Prosjektdeltaker
  • Radovan Jirik Prosjektdeltaker
  • Hilde Løland Von Volkmann Prosjektdeltaker
  • Spiros Kotopoulis Prosjektdeltaker
  • Fredrik Eriksen Sævik Ph.d.-kandidat
  • Trygve Hausken Prosjektdeltaker
  • Frank Pfeffer Prosjektdeltaker
  • Sabine Maria Leh Prosjektdeltaker
  • Kim Nylund Prosjektleder
  • Odd Helge Gilja Hovedveileder
  • Gülen Arslan Lied Prosjektdeltaker
  • Knut Matre Prosjektdeltaker
  • Michiel Postema Prosjektdeltaker

eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT

Alle henvendelser rettes til Faglig rapportering, Helse Vest

Personvern  -  Informasjonskapsler